MGMT and glioblastoma: In a single arm phase II trial, enzastaurin, a protein kinase C inhibitor, administered before, concomitantly with, and after radiotherapy in GBM patients with unmethylated MGMT gene promoter, did not achieve the primary endpoint of PFS at 6 months (36).